secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001104659-24-062257
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics doses first participants in Phase 1a trial of anti-tau antibody VY-TAU01 for Alzheimer's
--------------------------------------------------------------------------------

- First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.
- Trial is randomized, double-blind, placebo-controlled, evaluating safety and PK in healthy adult volunteers.
- Study conducted at a single U.S. site; expected to enroll approximately 48 patients across multiple cohorts.
- VY-TAU01 designed to inhibit spread of pathological tau in Alzheimer's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924062257/0001104659-24-062257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924062257/tm2414591d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer